| All study subjects (n = 28) | Subjects completing study (n = 19) | |
---|---|---|---|
Age | 64.6 ± 10.4 years | 65.7 ± 10.8 years | |
Gender (males) | 17/28 (61%) | 16/19 (84%) | |
Duration of Diabetes Mellitus | 7.2 ± 3.9 years | 7.5 ± 4.1 years | |
Duration of Neuropathic Symptoms | 5.7 ± 4.1 years | 6.0 ± 4.3 years | |
Concomitant Diabetic | Â | Â | |
Complications Present (other than neuropathy) | 5/28 (18%) | 3/19 (16%) | |
Other Neuropathic Pain Medications Used | 1.2 ± 1.1 | 1.4 ± 1.2 | |
Weight (kg) | 96.3 ± 26.8 | 94.6 ± 25.9 | |
Height (cm) | 170.9 ± 7.6 | 169.7 ± 7.8 | |
Sitting Systolic Blood Pressure (mm Hg) | 141 ± 18 | 139 ± 18 | |
Sitting Heart Rate (/min) | 72 ± 10 | 74 ± 12 | |
Standing Systolic Blood Pressure (mm Hg) | 140 ± 19 | 136 ± 20 | |
Standing Heart Rate (/min) | 73 ± 12 | 73 ± 13 | |
Utah Early Neuropathy | 16.3 ± 9.6 | 16.2 ± 6.5 | |
Score | Â | Â | |
Douleur Neuropathique 4 Score | 7.6 ± 1.0 | 6.9 ± 0.9 | |
 |  | Block 1 Pregabalin Intervention | Block 1 Placebo Intervention |
Baseline Visual Analog Pain Score |  | 6.1 ± 1.6 | 7.1 ± 1.3 |
Average Pregabalin |  | 205.8 ± 28.9 | 188.1 ± 39.8 |
Dosage Achieved (mg) | Â | Â | Â |
Other Neuropathic Pain Medications Used |  | 1.4 ± 1.2 | 1.4 ± 1.2 |